Recurrent Glioblastoma Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
DelveInsight's, 'Recurrent Glioblastoma Pipeline Insight 2025' report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Recurrent Glioblastoma pipeline landscape. It covers the Recurrent Glioblastoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Recurrent Glioblastoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Recurrent Glioblastoma Research. Learn more about our innovative pipeline today! @ Recurrent Glioblastoma Pipeline Outlook
Key Takeaways from the Recurrent Glioblastoma Pipeline Report
In May 2025, CNS Pharmaceuticals Inc. announced a study that is an open-label, multicenter, randomized, parallel, 2-arm, efficacy and safety study. Patients with GBM after failure of standard first line therapy will be randomized in a 2:1 ratio to receive berubicin or lomustine for the evaluation of OS. Additional endpoints will include response and progression outcomes evaluated by a blinded central reviewer for each patient according to RANO criteria.
In May 2025, In8bio Inc. conducted a Phase 1b/2 study is being conducted to determine if the experimental cell therapy is safe, tolerable and can delay the return of cancer in patients with a newly diagnosed or recurrent glioblastoma multiforme (GBM) in combination with standard chemotherapy treatment temozolomide (TMZ). If there is a 25% or greater improvement in survival in this study then the therapy should be studied further.
DelveInsight's Recurrent Glioblastoma pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Recurrent Glioblastoma treatment.
The leading Recurrent Glioblastoma Companies such as Ascletis, Genexine, PharmAbcine, VAXIMM AG, WPD Pharmaceuticals, Accendatech USA Inc., Midatech Ltd, MediciNova, Kadmon Corporation, LLC, Istari Oncology, Inc., Bristol-Myers Squibb, Novartis, Jiangsu Hengrui Medicine, Peloton Therapeutics, Inc., Karyopharm Therapeutics, VBL Therapeutics, Nerviano Medical Sciences, Acerta Pharma BV, Basilea Pharmaceutica, DNAtrix, Inc., NanoPharmaceuticals LLC, Erasca, Inc., Oblato, Inc., OX2 Therapeutics, Crimson Biopharm Inc., Merck Sharp & Dohme LLC, Transgene, CANbridge Life Sciences Ltd., Eli Lilly and Company, Arcus Biosciences, Inc., Incyte Corporation, BerGenBio ASA, Istari Oncology, Inc., and Chimerix and others.
Promising Recurrent Glioblastoma Pipeline Therapies such as Pembrolizumab, Olaparib, Temozolomide, BIBF1120, Chemotherapy, GX-I7, Bevacizumab, Bevacizumab, TTAC-0001, Cediranib and others.
Stay informed about the cutting-edge advancements in Recurrent Glioblastoma treatments. Download for updates and be a part of the revolution in care @ Recurrent Glioblastoma Clinical Trials Assessment
Recurrent Glioblastoma Emerging Drugs Profile
ASC40: Ascletis
ASC40 is an oral, selective inhibitor of fatty acid synthase (FASN), a key enzyme which regulates de novo lipogenesis (DNL). ASC40 inhibits energy supply and disturbs membrane phospholipid composition of tumor cells by blocking de novo lipogenesis. In January 2022, Ascletis Pharma Inc. announced the dosing of the first patient in the Phase III registration clinical trial of ASC40 combined with bevacizumab for treatment of recurrent glioblastoma (rGBM). The Phase II study, completed in the U.S., in patients with rGBM has shown that the objective response rate (ORR) for ASC40 plus Bevacizumab treatment was 65% including a complete response (CR) of 20% and a partial response (PR) of 45%.
GX-I7: Genexine
GX-I7 is a long-acting human IL-7 which is essential for homeostatic T cell proliferation and improves lymphopenia, typically induced by chemotherapy or radiation therapy. The safety has been proved via phase I clinical trial in healthy volunteers and phase Ib and Ib/2 Clinical trials are being conducted to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics and efficacy.
Olinvacimab: PharmAbcine
Olinvacimab is an anti-angiogenic antibody that neutralizes the VEGF/VEGFR2 pathway, thus inhibiting tumor growth and metastasis. It blocks the binding of all VEGFR ligands such as VEGF-A, VEGF-C and VEGF-D to VEGFR2. To gain nutrients and oxygen needed for growth, tumor cells release these VEGF ligands which promote angiogenesis (a formation of new blood vessels) that will enhance tumor blood supply. Binding of olinvacimab to VEGFR2 will result in the inhibition of VEGF-mediated tumor angiogenesis.
VXM01: VAXIMM AG
VXM01 is an oral T-cell immunotherapy that is designed to activate T-cells to attack the tumor vasculature and, in several tumor types, attack cancer cells directly. VXM01 carries the vascular endothelial growth factor receptor-2 (VEGFR2), which is highly overexpressed on the tumor vasculature and on certain cancer cells as the target gene. The active, T-cell-mediated destruction of tumor vasculature cells leads to an increased infiltration of various immune cells into tumor tissue (inflammation). In preclinical studies, a murine analog VXM01 vaccine showed broad anti-tumor activity in different tumor types. This activity was linked to a VEGFR2-specific T-cell response and was accompanied by the destruction of the tumor vasculature and increased immune cell infiltration. A Phase I/II trial evaluating VXM01 in combination with avelumab, a human anti-PD-L1 antibody, for the treatment of glioblastoma is ongoing. The trial is part of a collaboration agreement with Merck KGaA, Darmstadt, Germany and Pfizer Inc. VXM01 has received orphan designation from the European Commission and from the US Food and Drug Administration (FDA) for the treatment of glioblastoma.
The Recurrent Glioblastoma Pipeline Report Provides Insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Recurrent Glioblastoma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Recurrent Glioblastoma Treatment.
Recurrent Glioblastoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Recurrent Glioblastoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Recurrent Glioblastoma Market
Stay informed about the Recurrent Glioblastoma Pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Recurrent Glioblastoma Unmet Needs
Recurrent Glioblastoma Companies
Ascletis, Genexine, PharmAbcine, VAXIMM AG, WPD Pharmaceuticals, Accendatech USA Inc., Midatech Ltd, MediciNova, Kadmon Corporation, LLC, Istari Oncology, Inc., Bristol-Myers Squibb, Novartis, Jiangsu Hengrui Medicine, Peloton Therapeutics, Inc., Karyopharm Therapeutics, VBL Therapeutics, Nerviano Medical Sciences, Acerta Pharma BV, Basilea Pharmaceutica, DNAtrix, Inc., NanoPharmaceuticals LLC, Erasca, Inc., Oblato, Inc., OX2 Therapeutics, Crimson Biopharm Inc., Merck Sharp & Dohme LLC, Transgene, CANbridge Life Sciences Ltd., Eli Lilly and Company, Arcus Biosciences, Inc., Incyte Corporation, BerGenBio ASA, Istari Oncology, Inc., and Chimerix and others.
Recurrent Glioblastoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Inhalation
Inhalation/Intravenous/Oral
Intranasal
Intravenous
Intravenous/ Subcutaneous
NA
Oral
Oral/intranasal/subcutaneous
Parenteral
Subcutaneous
Recurrent Glioblastoma Products have been categorized under various Molecule types such as
Antibody
Antisense oligonucleotides
Immunotherapy
Monoclonal antibody
Peptides
Protein
Recombinant protein
Small molecule
Stem Cell
Vaccine
Transform your understanding of the Recurrent Glioblastoma Pipeline! See the latest progress in drug development and clinical research @ Recurrent Glioblastoma Market Drivers and Barriers, and Future Perspectives
Scope of the Recurrent Glioblastoma Pipeline Report
Coverage- Global
Recurrent Glioblastoma Companies- Ascletis, Genexine, PharmAbcine, VAXIMM AG, WPD Pharmaceuticals, Accendatech USA Inc., Midatech Ltd, MediciNova, Kadmon Corporation, LLC, Istari Oncology, Inc., Bristol-Myers Squibb, Novartis, Jiangsu Hengrui Medicine, Peloton Therapeutics, Inc., Karyopharm Therapeutics, VBL Therapeutics, Nerviano Medical Sciences, Acerta Pharma BV, Basilea Pharmaceutica, DNAtrix, Inc., NanoPharmaceuticals LLC, Erasca, Inc., Oblato, Inc., OX2 Therapeutics, Crimson Biopharm Inc., Merck Sharp & Dohme LLC, Transgene, CANbridge Life Sciences Ltd., Eli Lilly and Company, Arcus Biosciences, Inc., Incyte Corporation, BerGenBio ASA, Istari Oncology, Inc., and Chimerix and others.
Recurrent Glioblastoma Pipeline Therapies- Pembrolizumab, Olaparib, Temozolomide, BIBF1120, Chemotherapy, GX-I7, Bevacizumab, Bevacizumab, TTAC-0001, Cediranib and others.
Recurrent Glioblastoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Recurrent Glioblastoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay Ahead in Oncology Research–Access the Full Recurrent Glioblastoma Pipeline Analysis Today! @ Recurrent Glioblastoma Drugs and Companies
Table of Contents
Introduction
Executive Summary
Recurrent Glioblastoma: Overview
Pipeline Therapeutics
Therapeutic Assessment
Recurrent Glioblastoma – DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
ASC40: Ascletis
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
GX-I7: Genexine
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
VXM01: VAXIMM AG
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Recurrent Glioblastoma Key Companies
Recurrent Glioblastoma Key Products
Recurrent Glioblastoma- Unmet Needs
Recurrent Glioblastoma- Market Drivers and Barriers
Recurrent Glioblastoma- Future Perspectives and Conclusion
Recurrent Glioblastoma Analyst Views
Recurrent Glioblastoma Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
2 hours ago
- Globe and Mail
Canada, China, Mexico, Japan and EU urge Trump not to impose new airplane tariffs
Five nations and the European Union, as well as airlines and aerospace firms worldwide, urged the Trump administration not to impose new national security tariffs on imported commercial planes and parts, documents released on Tuesday showed. Airlines and planemakers have been lobbying President Donald Trump to restore the tariff-free regime under the 1979 Civil Aircraft Agreement that has yielded an annual trade surplus of US$75 billion for the U.S. industry. The documents made public by the U.S. Commerce Department bared concerns over the fallout of possible new tariffs expressed by companies as well as nations such as Canada, China, Japan, Mexico and Switzerland, besides the European Union. 'As reliable trading partners, the European Union and United States should strengthen their trade regarding aircraft and aircraft parts, rather than hinder it by imposing trade restrictions,' the EU wrote. It would consider its options 'to ensure a level playing field,' it added. Trump has already imposed tariffs of 10 per cent on nearly all airplane and parts imports. 'No country or region should attempt to support the development of its domestic aircraft manufacturing industry by suppressing foreign competitors,' the Chinese government wrote. Separately, U.S. planemaker Boeing cited a recent trade deal unveiled in May with Britain that ensures tariff-free treatment for airplanes and parts. Opinion: Carney was right to not retaliate against Trump's latest tariffs 'The United States should ensure duty-free treatment for commercial aircraft and their parts in any negotiated trade agreement, similar to its efforts with the United Kingdom,' Boeing told the Commerce Department in a filing. Mexico said in 2024 it exported US$1.45 billion in aircraft parts, just a tenth of the total, to the United States. The EU said it took U.S. exports of aircraft worth roughly US$12 billion, while exporting about $8 billion of aircraft to the U.S. In early May, the Commerce Department launched a 'Section 232' national security investigation into imports of commercial aircraft, jet engines and parts that could form the basis for even higher tariffs on such imports. Last week, Delta Air Lines and major trade groups warned of tariffs' impact on ticket prices, aviation safety and supply chains. 'Current U.S. tariffs on aviation are putting domestic production of commercial aircraft at risk,' Airbus Americas CEO Robin Hayes said in a filing. 'It is not realistic or sensible today to create a 100 per cent domestic supply chain in any country.' Boeing said it had been increasing U.S. content in its airplanes over the last decade and its newest airplanes, the 737 MAX 10 and 777X, would have 'more than 88 per cent domestically-sourced content.' The United Auto Workers union, which represents 10,000 aerospace workers, said it supports tariffs and domestic production quotas, adding that U.S. aerospace employment has fallen to 510,000 in 2024 from 850,000 in 1990. 'To safeguard the entire aerospace supply chain across the commercial and defense sectors, comprehensive tariffs and production quotas on several products are needed,' it said. JetBlue Airways opposed new tariffs, however, saying, 'Trade policy should reinforce, not destabilize, the proven systems that keep our aircraft flying safely and affordably.'
CTV News
2 hours ago
- CTV News
U.S. Court rules Trump's tariffs can stay in effect while appeal proceeds
President Donald Trump walks down the stairs of Air Force One upon his arrival at Joint Base Andrews, Md., Tuesday, June 10, 2025. (AP Photo/Luis M. Alvarez) WASHINGTON — A U.S. federal appeals court agreed on Tuesday that U.S. President Donald Trump's sweeping global tariffs will remain in place while a case is heard — extending an emergency stay granted after a lower court found the devastating duties unlawful. The United States Court of Appeals for the Federal Circuit found 'a stay is warranted under the circumstances.' It provides a temporary victory for the Trump administration as it hits its first legal barriers for realigning global trade. 'The Trump administration is legally using the powers granted to the executive branch by the Constitution and Congress to address our country's national emergencies of persistent goods trade deficits and drug trafficking,' said White House spokesman Kush Desai in an emailed statement Tuesday. 'The U.S. Circuit Court of Appeals' stay order is a welcome development, and we look forward to ultimately prevailing in court.' The U.S. Court of International Trade last month said Trump does not have the authority to wield tariffs on nearly every country through the use of the International Economic Emergency Powers Act of 1977. The act, usually referred to by the acronym IEEPA, is a national security statute that gives the U.S. president authority to control economic transactions after declaring an emergency. The ruling from the three-judge panel at the New York-based federal court in May said 'any interpretation of IEEPA that delegates unlimited tariff authority is unconstitutional.' It said 'the challenged tariff orders will be vacated,' representing a nationwide injunction against any further imposition of the duties. The Trump administration quickly was granted an emergency motion, essentially freezing the decision by the trade court that blocked the so-called 'Liberation Day' and fentanyl-related tariffs. The appeals court upheld that stay but noted the need for an expedited hearing, saying 'these cases present issues of exceptional importance warranting expedited en banc consideration.' A proposed schedule says arguments are expected in court by July 31. That means that countries will continue to be hit by those duties, for now. George Mason University law professor Ilya Somin called it an 'unfortunate decision.' Somin, along with the Liberty Justice Center, represents five American small businesses pushing against the tariffs. He noted that the court did go out of its way to indicate this is not a ruling on the merits, and ordered an expedited schedule for consideration of the case. 'We have a strong case, and I remain guardedly optimistic that the appellate court will ultimately see that the president's claim of virtually unlimited power to impose tariffs is blatantly illegal — which is what every court to have considered the issue so far has concluded,' Somin said in an email to The Canadian Press. Stock markets have been in turmoil and supply chains have been upended as Trump used unprecedented presidential power to enact his tariffs. Up until Trump's return to the White House, IEEPA had never been used by a president to impose tariffs. Trump hit Canada with economywide duties in March after he declared an emergency at the northern border related to the flow of fentanyl. He partially paused levies a few days later for imports that comply with the Canada-U.S.-Mexico Agreement on trade. U.S. government data shows a minuscule volume of fentanyl is seized at the northern border. Trump took his trade war to the world in April with duties on nearly every country saying America's trade deficits amounted to a national emergency. The president walked back the most devastating duties a few hours later but left a 10 per cent universal tariff in place for most countries. Trump said the 90-day pause would give countries time to negotiate a deal. The president said if countries didn't comply he would simply set tariff rates himself. White House Press Secretary Karoline Leavitt has said that the Supreme Court should 'put an end to this' and called the lower court's decision 'judicial overreach.' The appeal ruling will consider two different cases that were pushing against Trump's tariffs. One included the five American small businesses against Trump's worldwide tariffs, and the other stemmed from 12 states arguing against both the 'Liberation Day' duties and the fentanyl-related tariffs. At least seven lawsuits are challenging the tariffs. Lawyers for the businesses say IEEPA does not mention tariffs and the U.S. Constitution gives power over taxes and tariffs to Congress. They say Trump is misusing the statute. Lawyers for Arizona, Colorado, Connecticut, Delaware, Illinois, Maine, Minnesota, Nevada, New Mexico, New York, Oregon and Vermont argued that tariffs make U.S. trade policy dependent on Trump's whims. Thirty-three senators also filed an amicus brief — a legal submission from a group that's not party to the action — in the case, saying the duties would cause harm to small- and medium-sized businesses while also grabbing powers that should be assigned to Congress. 'Small businesses do not have cash-on-hand or capital reserves to pay the increased tariffs, nor can they quickly adapt to them by modifying supply chains,' it said. 'If they cannot pass on the tariff costs to consumers — which would create additional harms for... constituents — many face letting employees go or filing for bankruptcy. Even a few weeks of additional tariffs means small businesses will suffer irreparable harm.' Canada is also being hit with tariffs on steel, aluminum and automobiles. Trump used different powers under the Trade Expansion Act of 1962 to enact those duties. This report by The Canadian Press was first published June 10, 2025 Kelly Geraldine Malone, The Canadian Press
Globe and Mail
3 hours ago
- Globe and Mail
Analyst Outlook for American Financial Markets
Market Outlook (About (STA Research): Is a Canadian investment research company, consisting of Financial Professionals specializing in advanced stock research and analysis). Analysts have mixed expectations for the U.S. stock market for the remainder of 2025, reflecting a balance between cautious optimism and concerns over valuation and geopolitical risks and macro economic pressures. Bullish Outlook Several major financial institutions maintain a positive view for the remainder of 2025: Bank of America projects the S&P 500 to reach 6,666 by year-end, driven by anticipated earnings growth and potential interest rate cuts by the Federal Reserve. JPMorgan forecasts a 9% upside, targeting 6,500, supported by AI-driven investments and favorable global economic policies. Morgan Stanley sets a base case of 6,500, with a bull case of 7,400, contingent on continued economic momentum and policy support. . Cautious Outlook Conversely, some analysts express caution due to high valuations and potential economic headwinds: PIMCO warns that the equity risk premium is at historic lows, indicating that stocks may be overvalued relative to bonds, which could lead to market corrections. BCA Research anticipates a bearish phase in the first half of 2025, citing weakening consumer spending and potential recession risks. Sector-Specific Insights Analysts also provide guidance on sector performance: Small-cap stocks are expected to outperform in the second quarter, benefiting from attractive valuations and potential Federal Reserve rate cuts. Defensive sectors such as utilities and consumer staples are viewed favorably, offering stability amid market volatility. Technology and AI-related investments remain strong, with continued enthusiasm for advancements driving market interest. Top 5 Analyst Stock Picks For Q3 & Q4 1. Amazon (AMZN) Amazon's diverse revenue streams, including AWS, advertising, and logistics, position it for sustained growth. Analysts anticipate a reacceleration in AWS and potential growth in advertising, grocery, logistics, and Project Kuiper 2. Meta Platforms (META) Meta's investment in AI-powered applications, such as Llama 4, and its strong advertising recovery contribute to its growth prospects. The company has approximately 1 billion monthly active users for Meta AI. 3. Microsoft (MSFT) Microsoft's strategic partnerships and investments in AI, including collaborations with Fivetran and Fastino, enhance its growth prospects. The company's focus on AI-driven solutions positions it well for future gains. 4. Nvidia (NVDA) Nvidia is a leader in AI hardware, providing GPUs that power AI computing. The company's strong performance in 2024 and continued leadership in the industry contribute to its growth potential. 5. Salesforce (CRM) Salesforce's position as the #1 platform for integrated CRM services, coupled with its focus on AI-driven solutions, supports its growth prospects. The company's strong financials and market position make it a top pick for the upcoming quarters. Outlook The consensus among analysts for financial markets is a cautiously optimistic outlook for the near term and the remainder of 2025. While some anticipate market gains, others advise vigilance due to high valuations and economic uncertainties, and macro headwinds. Investors are encouraged to focus on sectors with strong fundamentals and consider a diversified approach to navigate potential market fluctuations.
